Company: ATRA
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-059322
Chunk: 20

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 20
---
oli was appointed to the Board in September 2024. Audit Committee The Board has determined that each member of the Audit Committee is independent under Nasdaq listing standards and Rule 10A-3(b)(1) promulgated under the Exchange Act. The Board has also determined that Mr. Fust is an “audit committee financial expert” within the meaning of SEC regulations. Each member of the Audit Committee has the requisite financial expertise required under the applicable requirements of Nasdaq. In arriving at this determination, the Board examined each Audit Committee member’s scope of experience and the nature of their employment in the corporate finance sector. The primary functions of this committee include, among others: • reviewing and pre-approving the engagement of our independent registered public accounting firm to perform audit services and any permissible non-audit services; • evaluating the performance of our independent registered public accounting firm and deciding whether to retain its services; • monitoring the rotation of partners on the engagement team of our independent registered public accounting firm; • reviewing our annual and quarterly financial statements and reports and discussing the statements and reports with our independent registered public accounting firm and management, including a review of disclosures under “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, and conferring with our independent registered public accounting firm and management regarding the scope, adequacy and effectiveness of internal control over financial reporting; • considering and approving or disapproving of related party transactions; • reviewing, with our independent registered public accounting firm and management, significant issues that may arise regarding accounting principles and financial statement presentation, as well as matters concerning the scope, adequacy and effectiveness of our financial controls; • assessing our financial risk assessment and management of those risks; • oversight of cyber risk management and the integrity of our information technology systems, processes and data, and our incident response plans and contingency plans; • reviewing and assessing our director’s and officer’s indemnification and insurance; • preparing the report required by the rules of the SEC to be included in our annual proxy statement or annual report;

<div align='center'>11</div>

reviewing our compliance with legal or regulatory requirements;

establishing procedures for the receipt, retention and treatment of complaints received by us regarding financial controls, accounting or auditing matters; and

reviewing and evaluating, at least annually, the performance of the Audit Committee and the adequacy of its charter.

The Audit Committee is briefed regularly on cybersecurity matters, such as our cybersecurity defense measures, current trends and cybersecurity incidents, including our responses to such incidents, if appropriate, and updates to